A Practical Guide to Using Biologics in Pediatric Dermatology

J Cutan Med Surg. 2024 Jan-Feb;28(1):59-67. doi: 10.1177/12034754231222415. Epub 2024 Jan 16.

Abstract

Psoriasis, hidradenitis suppurativa (HS), atopic dermatitis (AD), and chronic spontaneous urticaria (CSU), are common, immune-mediated, chronic, inflammatory skin diseases that can affect the pediatric population. While there is adequate evidence supporting the use of biologics in pediatric patients, concerns regarding safety and efficacy amongst healthcare providers are not uncommon. However, new emerging evidence in this population highlights the safety of biologic therapy, making it crucial to review and establish a practical guide for their use. This article describes a methodological framework for initiating biologics in the management of pediatric psoriasis, HS, AD, and CSU, with a special focus on baseline work-up, monitoring, dosing, and considerations in this population.

Keywords: atopic dermatitis; biologics; chronic spontaneous urticaria; hidradenitis suppurativa; pediatrics; psoriasis.

Publication types

  • Review

MeSH terms

  • Biological Products* / therapeutic use
  • Child
  • Chronic Urticaria*
  • Dermatitis, Atopic* / drug therapy
  • Dermatology*
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Psoriasis* / drug therapy
  • Skin

Substances

  • Biological Products